Spero Therapeutics, Inc. (SPRO)
1.21
-0.01
(-0.82%)
USD |
NASDAQ |
Sep 04, 16:00
1.21
0.00 (0.00%)
After-Hours: 20:00
Spero Therapeutics Research and Development Expense (Quarterly) : 3.434M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.434M |
| March 31, 2026 | 2.909M |
| December 31, 2025 | 5.592M |
| September 30, 2025 | 8.597M |
| June 30, 2025 | 10.67M |
| March 31, 2025 | 13.61M |
| December 31, 2024 | 28.84M |
| September 30, 2024 | 26.86M |
| June 30, 2024 | 23.72M |
| March 31, 2024 | 17.33M |
| December 31, 2023 | 16.52M |
| September 30, 2023 | 16.28M |
| June 30, 2023 | 9.162M |
| March 31, 2023 | 8.63M |
| December 31, 2022 | 14.73M |
| September 30, 2022 | 6.875M |
| June 30, 2022 | 7.882M |
| March 31, 2022 | 16.56M |
| Date | Value |
|---|---|
| December 31, 2021 | 17.17M |
| September 30, 2021 | 14.08M |
| June 30, 2021 | 14.31M |
| March 31, 2021 | 18.45M |
| December 31, 2020 | 13.01M |
| September 30, 2020 | 17.52M |
| June 30, 2020 | 15.47M |
| March 31, 2020 | 20.25M |
| December 31, 2019 | 25.43M |
| September 30, 2019 | 18.01M |
| June 30, 2019 | 12.03M |
| March 31, 2019 | 9.526M |
| December 31, 2018 | 9.127M |
| September 30, 2018 | 8.459M |
| June 30, 2018 | 7.374M |
| March 31, 2018 | 10.82M |
| December 31, 2017 | 12.50M |
| September 30, 2017 | 6.91M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | 10.50M |
| Fortress Biotech, Inc. | 0.805M |
| Kura Oncology, Inc. | 61.89M |
| Legend Biotech Corp. | 96.16M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |